title: Protease inhibitors and nucleosides: how many? when? An interview with Stefano Vella, MD. Interview by Mark Mascolini.
authors.forename: S
authors.initials: S
authors.lastname: Vella
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D018791:CD4 Lymphocyte Count; D016527:Drug Costs; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D012367:RNA, Viral / Q000097:blood
chemical_list: D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral